ATX-304 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
ATX-304 is a pill that switches on AMPK, the cell's fuel sensor. It has one 28-day pilot study in people with type 2 diabetes, plus recent mouse data. It is now sold as a research chemical and pitched as exercise in a pill or a metformin swap.
Evidence grade for ATX-304: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 1 human study where nobody was given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
1 human study where nobody was given it
2 effects reported, 2 unwanted, by people using it, not a trial
Goal pages: Fat loss and metabolism, Gut health
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
ATX-304 is a pill that switches on AMPK, the cell's fuel sensor. It is sold as exercise in a pill or a metformin swap. It has one short human study. It is sold as a research chemical, not a medicine.
What people take it for
- Better blood sugar.
- Exercise-like benefits without the exercise.
- Replacing metformin.
What studies in people showed
One small human study. People with type 2 diabetes, already on metformin, took it for 28 days. Their blood sugar control and the blood flow in their smallest vessels looked better. In mice, it lowered liver fat and damage. There is no longer trial and no long-term safety data. Nobody has compared it with metformin.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- No long-term safety data, and no published data on how long it lasts in the body.
- The only people who took it were also on metformin, so its effect alone is unknown.
Where these come from: All of this comes from the one short human study and the mouse study on this page. We have no user reports.
My bottom line
28 days in people already on metformin is a hint, not a reason to swap your meds. Walking after meals does a lot of what this claims, and we know it is safe.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none.
- Liver fat and liver health1 animal or lab study
35 of the 36 indexed goals have no study of any kind behind ATX-304
No study in people, animals or cells on this page reports a result for these. That does not prove ATX-304 does nothing for them. It does mean anything you have heard about ATX-304 and one of these did not come from a study cited here.
Show full evidence
What is ATX-304?
ATX-304 is a pill that switches on AMPK, the cell's fuel sensor. It has one 28-day pilot study in people with type 2 diabetes, plus recent mouse data. It is now sold as a research chemical and pitched as exercise in a pill or a metformin swap.
ATX-304 keeps AMPK switched on. It does this by stopping AMPK from being switched off, rather than by draining the cell's energy. In people with type 2 diabetes who were already on metformin, 28 days of it improved how they handled blood sugar and the blood flow in their smallest vessels. In mice, 2025 work showed less liver fat and less oxidative damage. Beyond that there is no trial of real benefit, no published data on how long it lasts in the body, and no long-term safety data. It got popular in 2026 after an influencer wrote it up and a seller added it to their catalog.
How does ATX-304 work?
It switches on AMPK, the cell's fuel sensor, by blocking the enzyme that would turn it off. It also makes mitochondria waste a little fuel as heat.
The evidence, in charts
Fig. 1a · how many people
1study in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
1 of 2 sources here is a study in people. The rest is not.
- Study in people · done in people150%
- Animal study · done in animals150%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2018 and 2025.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 380.2 Da
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for ATX-304, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2018The AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients
An early trial gave a hint, nothing more. People with type 2 diabetes, already on metformin, took O304 for 28 days. Their blood sugar control and the blood flow in their smallest vessels looked better afterwards. 28 days is a signal. It is not an answer, and the same paper holds the mouse work the idea came from.
28-day Phase 2a signal on glucose and perfusion.
- Animal study2025AMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching
In mice. It lowered liver fat and oxidative damage in fatty liver disease.
Reduced liver fat and oxidative stress in mice.
Where to buy ATX-304
2 sellers list ATX-304 in our latest read. They are ranked by trust score, then by archive rating, then by certificate tier, then by the lowest price per milligram. Archive evidence is counted before source-backed. Each path is out of 4, and the two are not added. A higher price does not raise the score. The letter is the certificate chip. 0 of them have a published certificate that names ATX-304.
Some seller links may pay this site when you buy through them. A payment never changes a seller's tier or rank, and no seller has a say in any page.
| Seller | Trust score | Vial sizes | From, per mg | Certificate for ATX-304 | Seller link |
|---|---|---|---|---|---|
| Luxe Peptides | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 100 mg | $1.70 | None found for ATX-304 | View |
| Pure Health Peptides | 25 InsufficientSource-backed 1 of 4. Archive evidence 0 of 4.C | 100 mg | $1.29 | None found for ATX-304 | View |
- LC Lab-confirmed: the issuing laboratory echoed this certificate back
- A Current certificate, independent laboratory named, laboratory not yet checked
- B Certificate published, but no laboratory link, older than a year, or the laboratory did not recognise the published lookup
- C No certificate could be read
Every listing and vial size for ATX-304 · How the trust score is counted
Sellers named on the price pages are ranked by certificate tier, then price, and any affiliate income is disclosed there. Naming a seller is not a recommendation to buy or use anything.
Common questions
Has ATX-304 been tested in people?
Not in a completed trial cited here. 1 human study where nobody was given it. ATX-304 is a pill that switches on AMPK, the cell's fuel sensor. It has one 28-day pilot study in people with type 2 diabetes, plus recent mouse data. It is now sold as a research chemical and pitched as exercise in a pill or a metformin swap.
What is the ATX-304 dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 1 human study where nobody was given it
Is ATX-304 FDA-approved?
Once tested as a drug; now sold as an unapproved research chemical
Is ATX-304 better than metformin?
Nobody has compared them. Its only human data is a 28-day pilot in people who were also taking metformin.
Latest reading on ATX-304
Blog posts about ATX-304, newest first.